Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
for Breast Cancer
1105 locations incl. Anchorage
Sponsor: NRG Oncology
Sex: Female·Age: 18 - 60
Code: NCT05879926·Phase 3·Recruiting·Listed May 2023